BioSpace News Archive

Drug Development

Novo Touts Phase I Data for Next-Generation Obesity Candidate

Novo Nordisk’s early-stage amylin and GLP-1 co-agonist elicited a 13.1% reduction in body weight, with an overall favorable safety profile, the Danish drugmaker reported Thursday at an investor event.

March 7, 2024
·
2 min read
·
Tristan Manalac
Deals

Cancer-Focused Boundless Bio to Go Public as 2024 IPO Rally Continues

The early-stage oncology startup filed for an initial public offering on Wednesday, seeking funds to help develop its novel cancer therapies targeting extrachromosomal DNA.

March 7, 2024
·
2 min read
·
Tristan Manalac
Drug Delivery

AstraZeneca Invests $827M in UK Footprint, Focuses on Vaccine Manufacturing and R&D

The Anglo-Swedish drugmaker is making the investment to bolster its vaccine manufacturing and research and development capabilities in the U.K.

March 7, 2024
·
2 min read
·
Tristan Manalac
Policy

Biden Calls for Expanding IRA’s Drug Price Negotiation Program

President Joe Biden has proposed expansions to the Inflation Reduction Act, including an increase in the annual number of prescription drugs that would be subject to price negotiations to 50, up from 20.

March 7, 2024
·
4 min read
·
Tristan Manalac
Policy

FDA Action Alert: Mirum, BMS, Madrigal and More

The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.

March 7, 2024
·
6 min read
·
Tristan Manalac
Drug Development

GSK Advances Blenrep’s Potential Comeback with Second Phase III Win

The antibody-drug conjugate beat the standard of care in second-line multiple myeloma, the company reported on Thursday, as it seeks to get the cancer drug back on the U.S. market.

March 7, 2024
·
2 min read
·
Nick Paul Taylor
Business

Gilead, Merus Ink Potential $1.5B Deal for T-Cell Engagers

Gilead Sciences is partnering with Dutch biotech Merus to find novel dual tumor-associated antigens that target tri-specific antibodies.

March 7, 2024
·
2 min read
·
Tyler Patchen
Biotech Beach

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization, announced the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029.

March 7, 2024
·
5 min read
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.

March 7, 2024
·
3 min read
Genetown

Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community

Calyx, a leading technology-enabled provider of Medical Imaging services and IRT/RTSM to drug developers, and Invicro, a next-generation quantitative imaging biomarker company and pre-eminent development partner to pharma sponsors, have agreed to combine their business.

March 7, 2024
·
4 min read